Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE:MDT) has received FDA approval for its MiniMed™ 770G hybrid closed-loop insulin pump system, enhancing diabetes management for children as young as 2. This advanced system includes SmartGuard™ technology with smartphone connectivity, allowing caregivers to monitor real-time glucose levels and share data with clinicians. The MiniMed 770G aims to improve clinical outcomes based on evidence from a clinical study, indicating no severe hypoglycemia or device-related adverse events. Orders for the system will begin in the United States this week.
DUBLIN, Aug. 29, 2020 – Medtronic (NYSE: MDT) announced positive clinical trial results for its Arctic Front™ Advance Cryoballoon and Freezor® MAX Catheter. In the STOP-AF First trial, cryoablation proved superior to antiarrhythmic drugs (AAD) for treating recurrent symptomatic paroxysmal atrial fibrillation (PAF), with a 75% success rate compared to 45% for AAD. The Cryo-FIRST trial further showed significant quality of life improvements with the cryoablation system. The Arctic Front Advance is FDA-approved for treating symptomatic recurrent persistent AF, expanding treatment options for patients.
Medtronic plc (NYSE: MDT) reported Q1 fiscal 2021 revenue of $6.5 billion, a 13% decline as reported and 17% organic. GAAP diluted EPS fell to $0.36, with non-GAAP diluted EPS at $0.62, both down 51%. U.S. revenue decreased 14%, and non-U.S. developed market revenue fell 8%. Emerging markets revenue was down 18%. Despite a recovery in procedure volumes, significant declines in various segments, including Cardiac and Vascular Group and Minimally Invasive Therapies Group, were observed. Medtronic is not providing formal financial guidance due to pandemic uncertainty.
Medtronic plc (NYSE:MDT) has appointed Kevin Lofton as an independent director, effective September 15, 2020. Lofton, a seasoned healthcare executive, has extensive experience leading major hospital systems and was most recently CEO of CommonSpirit Health. His appointment is expected to provide the board with valuable insights in navigating the evolving healthcare landscape. Lofton has been recognized multiple times as one of healthcare's most influential figures and is currently the lead independent director at Gilead Sciences.
Medtronic plc (NYSE: MDT) announced a cash dividend of $0.58 per ordinary share for Q2 FY2021, marking a 7% increase from the prior year. This dividend reflects Medtronic's ongoing commitment to returning value to shareholders and continues its record as a member of the S&P 500 Dividend Aristocrats index, having raised dividends for 43 consecutive years. The dividend will be payable on October 16, 2020, to shareholders on record by the close of business on September 25, 2020.
Medtronic announced FDA approval for revised commercial labeling of the Evolut™ TAVR platform, expanding treatment options for patients with bicuspid severe aortic stenosis. The updated guidelines address anatomical characteristics and highlight favorable clinical outcomes, with a 1.3% rate of mortality or disabling stroke within 30 days after the procedure. The Evolut platform is now indicated for symptomatic severe AS patients across all risk categories, enhancing its adoption globally. This revision reflects Medtronic's commitment to providing innovative solutions in heart valve therapies.
Medtronic has launched the ELITE study, a prospective, multicenter trial aimed at confirming the long-term safety and efficacy of its InterStim™ Micro system for treating overactive bladder, fecal incontinence, and non-obstructive urinary retention. The study will enroll 160 patients across 40 sites globally, assessing patient-reported outcomes and quality of life over two years. The InterStim Micro received FDA approval on August 3, 2020, and is positioned as the gold standard in sacral neuromodulation therapy, potentially addressing the needs of millions of patients suffering from bladder and bowel issues.
Medtronic announced the publication of results from the IN.PACT AV Access trial in The New England Journal of Medicine, highlighting the efficacy of the IN.PACT™ AV drug-coated balloon (DCB) for patients with end-stage renal disease (ESRD). The trial involved 330 subjects across three countries and demonstrated a significant reduction in the need for reinterventions—56% fewer than standard treatments—while maintaining a higher primary patency rate (82.2% vs. 59.5%). The study emphasizes the potential for improved patient quality of life and reduced healthcare costs.
Medtronic plc (NYSE: MDT) is set to announce its financial results for the first quarter of fiscal year 2021 on August 25, 2020. The results will be communicated through a news release at approximately 5:45 a.m. CDT, covering the period ending July 31, 2020. A webcast will follow at 7:00 a.m. CDT to discuss these results, accessible at http://investorrelations.medtronic.com/. Additionally, Medtronic plans to report subsequent quarterly results on November 24, 2020, February 23, 2021, and May 27, 2021.
Medtronic announced the first implant of its FDA-approved InterStim Micro neurostimulator for sacral neuromodulation (SNM) therapy at Cleveland Clinic. This device, the smallest rechargeable SNM system, enhances bladder and bowel control for over 55 million Americans suffering from overactive bladder (OAB) and fecal incontinence (FI). Key features include a quick recharge time under an hour, a battery life of 15 years, and MRI compatibility without impedance checks, aimed at improving patient quality of life.
